2. Correct. Given that the majority of SW jobs, especially the highest paying ones, were located in the U.S. this is a net benefit to anyone living outside the U.S. even before you take cost into consideration. More American jobs opened up to a Londoner than global jobs opened up to someone living in SF.
3. Efficiency approximately = lower costs. In this case costs = developer salaries.
So you’re right. We got more efficient. We reduced the average cost of developer salaries per job. Since very few people are willing to take a pay cut this means jobs are moving/will move to places where people are willing to work for less.
Microsoft Research has a ton of people working on theoretical CS.
Biology - there is a ton of research in agriculture too - e.g. Monsanto and GMO seeds.
I don’t think there are current private organizations doing research similar to what Bell Labs did as the current corporate-governance systems wouldn’t allow for it.
Currently, industry research is more for profit-maximization at the expense of greater human prosperity/economic growth: such as you mention Monsanto making patented seeds, increasing profits by disallowing farmers to regrow crops more cheaply which otherwise could’ve been passed onto consumers/wider society.
I can only hope at the end of the day their data doesn't end up in the wrong hands. It is their most valuable asset, and this is a way bigger deal than it seems.
I think there are negative externalities if the data is sold to insurance firms — who can use the genomic information in litigation and policy rejections — or if the data is sold to some sort of powerful, pro-eugenics political organization. The insurance externalities likely can be mitigated with minimal legislation (protecting consumers in a similar manner to how we protect those with pre-existing conditions) and it is reasonable to assume pro-eugenics political groups wouldn’t be any less dangerous without this genomic data available.
Thus, I struggle to see how this data changing hands would be especially detrimental to society. One could contend a moral dilemma will arise from future developments in cloning, but would it? We already have clones in the form of identical twins, and their existence does not seem to create many, if any, especially problematic moral dilemmas. Maybe people are worried that society will start cloning celebrities and famous intellectuals instead of having babies more naturally — creating a world of designer babies where the diversity of thought and talent shrinks in a “tragedy of the commons”-esque dilemma — but I don’t think this is people’s issue because most people frame their qualms as more of a personal privacy issue. Moreover, designer babies issue I describe would likely become an issue with or without cloning.
There are issues that come to mind regarding genomics in commerce — such as the ethics and market incentives of patenting certain genomic patterns — but again I don’t see how this 23andMe data changing hands make this issue any more pressing than before.
On the other hand, my instinct (which I have learned to never blindly trust) is that making the data more widely available may make it cheaper and easier for researchers to make impactful discoveries. Therefore, my biggest worry with the change of ownership is that the new owners may keep the data behind a bigger wall.
Previously, one could argue that choosing to give your labor to an industry with superior values and alignment of incentives over another would provide the most good as that industry will naturally assert and perpetuate its values and personal interest throughout society and government. However, it’s unclear what industry has superior values and best alignment of incentives with society.